See more : Universal Global Hub Inc. (UGHB) Income Statement Analysis – Financial Results
Complete financial analysis of Awakn Life Sciences Corp. (AWKNF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Awakn Life Sciences Corp., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Mitsubishi HC Capital Inc. (8593.T) Income Statement Analysis – Financial Results
- Sugentech Inc. (253840.KQ) Income Statement Analysis – Financial Results
- DouYu International Holdings Limited (DOYU) Income Statement Analysis – Financial Results
- Resideo Technologies, Inc. (REZI) Income Statement Analysis – Financial Results
- Selected Investments Equities (SIIEQT.CO) Income Statement Analysis – Financial Results
Awakn Life Sciences Corp. (AWKNF)
About Awakn Life Sciences Corp.
Awakn Life Sciences Corp., a biotechnology company, engages in the researching, developing, operations, and delivering of psychedelic therapeutics to treat addiction and other mental health conditions in the United Kingdom and Europe. The company is headquartered in Toronto, Canada.
| Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Revenue | 87.37K | 1.50M | 236.04K | 0.00 |
| Cost of Revenue | 18.30K | 603.53K | 512.87K | 0.00 |
| Gross Profit | 69.08K | 891.81K | -276.83K | 0.00 |
| Gross Profit Ratio | 79.06% | 59.64% | -117.28% | 0.00% |
| Research & Development | 827.82K | 1.57M | 3.31M | 0.00 |
| General & Administrative | 2.73M | 4.06M | 4.40M | 666.73K |
| Selling & Marketing | 439.59K | 1.40M | 1.63M | 103.18K |
| SG&A | 3.17M | 8.51M | 6.54M | 823.07K |
| Other Expenses | 0.00 | -2.37K | 10.35K | 0.00 |
| Operating Expenses | 87.37K | 10.08M | 9.85M | 1.46M |
| Cost & Expenses | 4.00M | 10.69M | 10.03M | 1.46M |
| Interest Income | 87.67K | 305.79K | 0.00 | 13.10K |
| Interest Expense | 0.00 | 266.52K | 205.43K | 0.00 |
| Depreciation & Amortization | 18.30K | 14.41K | 181.41K | 84.00 |
| EBITDA | -3.91M | -5.26M | -16.08M | -840.22K |
| EBITDA Ratio | -4,473.00% | -574.33% | -4,072.48% | 0.00% |
| Operating Income | -3.93M | -9.19M | -9.79M | -840.30K |
| Operating Income Ratio | -4,493.94% | -614.69% | -4,149.34% | 0.00% |
| Total Other Income/Expenses | 255.42K | 306.31K | -6.86M | -652.12K |
| Income Before Tax | -3.67M | -9.65M | -16.47M | -1.48M |
| Income Before Tax Ratio | -4,201.61% | -645.44% | -6,978.45% | 0.00% |
| Income Tax Expense | 0.00 | -509.02K | -525.87K | -215.30K |
| Net Income | -5.10M | -9.14M | -15.95M | -1.26M |
| Net Income Ratio | -5,840.14% | -611.40% | -6,755.65% | 0.00% |
| EPS | -0.09 | -0.36 | -0.73 | -0.10 |
| EPS Diluted | -0.13 | -0.36 | -0.73 | -0.10 |
| Weighted Avg Shares Out | 39.68M | 25.20M | 21.96M | 12.63M |
| Weighted Avg Shares Out (Dil) | 29.07M | 25.20M | 21.96M | 12.63M |
Awakn Life Sciences Announces Closing of Tranche of Private Placement
Toronto, Ontario--(Newsfile Corp. - June 4, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company") a clinical-stage biotechnology company developing medication-assisted treatments for addiction with a near-term focus on Alcohol Use Disorder, is...
CSE Bulletin: Reinstatement - Awakn Life Sciences Corp. (AWKN)
Toronto, Ontario--(Newsfile Corp. - Le 31 mai/May 2024) - Effective immediately, Awakn Life Sciences Corp. will be reinstated for trading. The Company has rectified the situation that gave rise to the suspension.
Awakn Life Sciences Discusses Filing of Financial Statements
Toronto, Ontario--(Newsfile Corp. - May 2, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a clinical-stage biotechnology company developing medication-assisted treatments for addiction with a near-term focus on Alcohol Use Disorder (AUD),...
Awakn Life Sciences Announces Closing of Tranche of Private Placement
Toronto, Ontario--(Newsfile Corp. - April 17, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company") a clinical-stage biotechnology company developing medication-assisted treatments for addiction with a near-term focus on Alcohol Use Disorder (AUD),...
Awakn Life Sciences Announces Launch of Licensing Partnership Agreement with Oklahoma Based Clinic
Awakn also announces Private Placement Toronto, Ontario--(Newsfile Corp. - April 3, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company") a clinical-stage biotechnology company developing medication-assisted treatments for addiction with a near-term focus...
Canadian Securities Exchange Welcomes Listing of Awakn Life Sciences Corp
Toronto, Ontario--(Newsfile Corp. - February 13, 2024) - The Canadian Securities Exchange ("CSE" or "the Exchange") today welcomed the listing of Awakn Life Sciences Corp., a clinical-stage biotechnology company developing medication-assisted treatments for addiction with a near-term focus on Alcohol...
CSE Bulletin: New Listing - Awakn Life Sciences Corp. (AWKN)
Toronto, Ontario--(Newsfile Corp. - Le 9 février/February 2024) - The common shares of Awakn Life Sciences Corp. have been approved for listing on the CSE. Listing and disclosure documents will be available at www.thecse.com on the trading date.
Awakn Life Sciences Announces Listing on the Canadian Securities Exchange
Toronto, Ontario--(Newsfile Corp. - February 12, 2024) - Awakn Life Sciences Corp. (CBOE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a clinical-stage biotechnology company developing medication-assisted treatments for addiction with a near-term focus on Alcohol Use Disorder ("AUD"), is pleased to...
Awakn Life Sciences Announces Conditional Approval of CSE Listing
Toronto, Ontario--(Newsfile Corp. - February 5, 2024) - Awakn Life Sciences Corp. (CBOE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a clinical-stage biotechnology company developing medication-assisted treatments for addiction with a near-term focus on Alcohol Use Disorder ("AUD"), is pleased to...
Awakn Life Sciences Completes Successful Investigative Study to Establish Dissociative Effect of a Proprietary Sublingual S-Ketamine Oral Thin Film Formulation in Harmful Drinkers
Awakn Designates Program AWKN-002 for Alcohol Use Disorders in the US Market Toronto, Ontario--(Newsfile Corp. - January 24, 2024) - Awakn Life Sciences Corp. (CBOE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a clinical-stage biotechnology company developing medication-assisted treatments for addiction...
Source: https://incomestatements.info
Category: Stock Reports